Literature DB >> 24217974

Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells.

J Cai1, S Chen, W Zhang, Y Wei, J Lu, J Xing, Y Dong.   

Abstract

BACKGROUND: 5-Fluorouracil (5-Fu) is a commonly used chemotherapeutic agent in clinical care of breast cancer patients. However, the mechanism of how the 5-Fu works is complex and still largely unknown.
OBJECTIVE: The objective of this study was to understand the mechanism further and explore the new targets of 5-Fu.
METHODS: The differentially expressed proteins induced by 5-Fu in human breast cancer MCF-7 cells were identified by proteomic analysis. Four differentially expressed proteins were validated using Western blot and quantitative real-time reverse-transcription polymerase chain reaction analysis for protein and mRNA levels. The effect of 5-Fu on MCF-7 cells was determined by cell viability assay, transmission electron microscopy and flow cytometry analysis.
RESULTS: 5-Fu dose-dependently inhibited cell proliferation with the IC50 value of 98.2 μM. 5-Fu also induced obviously morphological change and apoptosis in MCF-7 cells. Twelve differentially expressed proteins involved in energy metabolism, cytoskeleton, cellular signal transduction and tumor invasion and metastasis were identified.
CONCLUSION: These results may provide a new insight into the molecular mechanism of 5-Fu in therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217974     DOI: 10.1007/s12094-013-1127-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  RACK1: A superior independent predictor for poor clinical outcome in breast cancer.

Authors:  Xi-Xi Cao; Jing-Da Xu; Xiao-Li Liu; Jia-Wen Xu; Wen-Juan Wang; Qing-Quan Li; Qi Chen; Zu-De Xu; Xiu-Ping Liu
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

Review 2.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma.

Authors:  Yuanyuan Ruan; Linlin Sun; Yuqing Hao; Lijing Wang; Jiejie Xu; Wen Zhang; Jianhui Xie; Liang Guo; Lei Zhou; Xiaojing Yun; Hongguang Zhu; Aiguo Shen; Jianxin Gu
Journal:  J Clin Invest       Date:  2012-06-01       Impact factor: 14.808

4.  MBP-1 mediated apoptosis involves cytochrome c release from mitochondria.

Authors:  Asish K Ghosh; Mainak Majumder; Robert Steele; Ta-Jen Liu; Ratna B Ray
Journal:  Oncogene       Date:  2002-04-25       Impact factor: 9.867

5.  Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.

Authors:  I Garrido-Laguna; M L Amador; J Ruiz; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

6.  RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67.

Authors:  Zhi Wang; Ben Zhang; Lu Jiang; Xin Zeng; Yu Chen; Xiaodong Feng; Yu Guo; Qianming Chen
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

7.  Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma.

Authors:  Udo Roth; Hanieh Razawi; Julia Hommer; Katja Engelmann; Tilo Schwientek; Stefan Müller; Stephan E Baldus; Georgios Patsos; Anthony P Corfield; Christos Paraskeva; Franz-Georg Hanisch
Journal:  Proteomics       Date:  2010-01       Impact factor: 3.984

8.  Clinical significance of FOXP3 expression in human gliomas.

Authors:  L Wang; B Zhang; X Xu; S Zhang; X Yan; F Kong; X Feng; J Wang
Journal:  Clin Transl Oncol       Date:  2013-04-12       Impact factor: 3.405

Review 9.  Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis.

Authors:  Vanessa Y Tan; Sarah J Lewis; Josephine C Adams; Richard M Martin
Journal:  BMC Med       Date:  2013-02-26       Impact factor: 8.775

10.  A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

Authors:  Cristina Gravalos; Antonieta Salut; Carlos García-Girón; Rocío García-Carbonero; Ana Isabel León; Isabel Sevilla; Joan Maurel; Beatriz Esteban; Eduardo García-Rico; Adolfo Murias; Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

View more
  2 in total

1.  Itraconazole inhibits the proliferation of gastric cancer cells in vitro and improves patient survival.

Authors:  Ke Lan; Ron Yan; Kun Zhu; Wenhan Li; Zisen Xu; Chengxue Dang; Kang Li
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

2.  Base-Mediated Coupling Reactions of Benzenesulfonyl Azides with Proline: Synthesis of Proline-Derived Benzenesulfonamides.

Authors:  Hongyan Liu; Bin Zhang; Wei Zhao; Xiao Yu; Wenjing Zhu; Chengcai Xia; Yanmeng Zhou
Journal:  ACS Omega       Date:  2021-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.